{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062968","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.262945+00:00","generated_at":"2026-06-08T04:57:43.841020+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kintara suspends VAL-083 after GBM AGILE failure; Q1 net loss $3M, cash $0.2M","bullets":["Topline GBM AGILE results showed VAL-083 did not perform better than standard of care; development suspended.","Focus shifts to REM-001 for cutaneous metastatic breast cancer; SBIR grant of $2.0M from NIH to support study.","Cash and cash equivalents $0.2M at Sep 30, 2023; raised ~$1.0M net in Nov 2023 via ATM facility.","Net loss $3.0M ($1.83/share) vs $4.6M ($3.39/share) in prior-year Q1; R&D and G&A expenses decreased.","Company evaluating strategic options to maximize shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062968","json":"https://secwatch.observer/filing/0000950170-23-062968.json","markdown":"https://secwatch.observer/filing/0000950170-23-062968.md","text":"https://secwatch.observer/filing/0000950170-23-062968.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023062968/0000950170-23-062968-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023062968/ktra-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:57:43.841020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7cc267ea18f31306558a742fc2b1521a910db531","claim":"TuHURA Biosciences, Inc./NV reported fiscal first quarter ended September 30, 2023 results: net income approximately $3.0 million, or $1.83 per share, EPS $1.83 per share (basic and diluted loss per share from net loss attributable to common stockholders).","evidence_excerpt":"For the three months ended September 30, 2023, Kintara reported a net loss of approximately $3.0 million, or $1.83 per share, compared to a net loss of approximately $4.6 million, or $3.39 per share, for the three months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023062968/0000950170-23-062968-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal first quarter ended September 30, 2023"},{"label":"Net income","value":"approximately $3.0 million, or $1.83 per share"},{"label":"EPS","value":"$1.83 per share (basic and diluted loss per share from net loss attributable to common stockholders)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}